# Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

> **NCT06389682** · PHASE1,PHASE2 · COMPLETED · sponsor: **Norroy Bioscience Co., LTD** · enrollment: 19 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma Metastatic

## Interventions

- **DRUG:** 68Ga-NYM005 injection

## Key facts

- **NCT ID:** NCT06389682
- **Lead sponsor:** Norroy Bioscience Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-17
- **Primary completion:** 2025-01-08
- **Final completion:** 2025-01-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06389682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06389682, "Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06389682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*